Provided by Tiger Fintech (Singapore) Pte. Ltd.

Amicus Therapeutics

6.21
+0.23003.85%
Post-market: 6.210.00000.00%16:37 EDT
Volume:6.70M
Turnover:41.61M
Market Cap:1.91B
PE:-64.60
High:6.31
Open:6.17
Low:6.09
Close:5.98
Loading ...

Company Profile

Company Name:
Amicus Therapeutics
Exchange:
NASDAQ
Establishment Date:
2002
Employees:
499
Office Location:
47 Hulfish Street,Princeton,New Jersey,United States
Zip Code:
08542
Fax:
609 662 2001
Introduction:
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. The company also develops AT-GAA, a novel treatment paradigm for Pompe disease; and enzyme replacement therapies for Pompe diseases. It has collaboration and license agreements with Nationwide Children's Hospital; University of Pennsylvania; and GlaxoSmithKline. The company was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania.

Directors

Name
Position
John F. Crowley
Chairman and Chief Executive Officer
Bradley L. Campbell
Director,President and Chief Operating Officer
Burke W. Whitman
Director
Craig Wheeler
Director
Glenn P. Sblendorio
Director
Lynn D. Bleil
Director
Margaret G. McGlynn
Director
Michael A. Kelly
Director
Michael Raab
Director
Robert Essner
Director

Shareholders

Name
Position
John F. Crowley
Chairman and Chief Executive Officer
Bradley L. Campbell
Director,President and Chief Operating Officer
Daphne Quimi
Chief Financial Officer
David M. Clark
Chief People Officer
Ellen S. Rosenberg
Chief Legal Officer and Corporate Secretary
Hung Do
Chief Science Officer
Samantha Prout
Vice President and Global Controller